Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Resectable NSCLC
NCT04506242Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Major Pathological Response Rate up to 12 weeks. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04506242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506242.